ImmunityBio Faces Significant Legal Troubles Following FDA's Warning on Misleading Cancer Treatment Claims

ImmunityBio's Legal Troubles: A Deep Dive

ImmunityBio, Inc. (NASDAQ: IBRX), a biotechnology firm that specializes in developing immunotherapies, is currently in hot water following a class action lawsuit that has garnered significant investor concern. The company’s stock took a massive hit, plunging more than 21% on March 24, 2026, after the U.S. Food and Drug Administration (FDA) issued a warning letter criticizing the efficacy claims made by Dr. Patrick Soon-Shiong, ImmunityBio's executive chairman and Chief Scientific and Medical Officer.

In January of this year, during a provocative podcast titled Is the FDA BLOCKING Life Saving Cancer Treatments?, Dr. Soon-Shiong posited that while ImmunityBio's lead product, Anktiva, is FDA-approved specifically for non-muscle invasive bladder cancer (NMIBC), it has the potential to treat all cancers. These assertions caught the attention of the FDA, which quickly characterized those statements as misleading, thereby triggering a formal investigation. Furthermore, the FDA determined that promotional materials, including a related TV advertisement, misrepresented Anktiva's capabilities and the benefits it offers to cancer patients.

The law firm Hagens Berman, which is spearheading the class action against ImmunityBio, has stressed the gravity of the situation, stating that the misleading claims have not only led to a significant loss of trust among investors but also raised serious public health concerns. The firm is now looking to represent those who acquired ImmunityBio shares between January 19, 2026, and March 24, 2026, encouraging affected investors to come forward.

Why Did the Stock Drop?

The fallout from the FDA's warning letter has been severe. Following the public disclosure of the FDA’s concerns, ImmunityBio saw its market capitalization diminish by nearly $2 billion almost overnight. The FDA's letter specified that the false impressions conveyed through recent advertising suggest that Anktiva is capable of curing and preventing all forms of cancer, a claim unsupported by clinical data. “We are not aware of data that support the efficacy claims… that Anktiva can ‘cure’ cancer,” the FDA stated, which further undermines the credibility of ImmunityBio’s promotional assertions.

The Consequences of Misleading Claims

The ongoing investigations by Hagens Berman come amid broader scrutiny concerning corporate accountability in the pharmaceutical industry. The firm has a history of pursuing cases against companies deemed to have engaged in deceptive practices, and they are eager to hold ImmunityBio accountable for potentially misleading investors. Attorney Reed Kathrein of Hagens Berman openly stated the firm is dedicated to examining whether ImmunityBio intentionally deceived its investors regarding Anktiva's efficacy and its indications.

With the class action lawsuit now underway and an impending deadline for investors to register their claims set for May 26, 2026, there is a looming sense of uncertainty around the future of ImmunityBio. Investors who believe they have sustained significant losses, or those with pertinent information, are encouraged to contact the firm for a confidential consultation.

Looking Ahead

As ImmunityBio continues to navigate this turbulent phase, the implications for both the company and the broader biotech industry remain to be seen. The $2 billion market cap loss signifies a stark reminder of how quickly fortunes can change in this sector, particularly when accountability and transparency are compromised.

For worried investors, the situation serves as a cautionary tale, illustrating the risks associated with companies whose promotional practices may not align with FDA regulations. The outcome of this case could set a significant precedent in investor protection and corporate honesty.

Conclusion

In conclusion, ImmunityBio is currently embroiled in a lawsuit that not only threatens its future but also raises questions about the ethical obligations of companies in the biotech sector. Stakeholders watch closely as this situation unfolds, understanding that trust and integrity are paramount in maintaining investor confidence and ensuring public health safety. Investors are advised to stay informed and consider their options as the class action progresses.